Johannes Breyer1, Ralph M Wirtz2,3, Wolfgang Otto4, Philipp Erben5, Thomas S Worst5, Robert Stoehr6, Markus Eckstein6, Stefan Denzinger4, Maximilian Burger4, Arndt Hartmann6. 1. Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de. 2. STRATIFYER Molecular Pathology GmbH, Cologne, Germany. 3. Institute of Pathology, St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany. 4. Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. 5. Department of Urology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 6. Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
Abstract
INTRODUCTION AND OBJECTIVES: Checkpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuring method using RNA quantification. MATERIALS AND METHODS: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder. mRNA expression of PD1, PDL1 and CD3 was measured by single step RT-qPCR and correlated to clinicopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS) and carcinoma-specific survival (CSS). RESULTS: We have analyzed 334 patients with NMIBC at stage pT1 for mRNA analysis. Data from 296 patients (79% male, median age: 72 years) could be used. Spearman correlation revealed significant associations between mRNA expressions of PD1/PDL1 (ρ: 0.6024, p < 0.0001), CD3/PDL1 (ρ: 0.5728, p < 0.0001) and CD3/PD1 (ρ: 0.7005, p < 0.0001). Kaplan-Meier analysis revealed that high PDL1 mRNA expression (≥ 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021]. CONCLUSION: High mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy.
INTRODUCTION AND OBJECTIVES: Checkpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuring method using RNA quantification. MATERIALS AND METHODS: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder. mRNA expression of PD1, PDL1 and CD3 was measured by single step RT-qPCR and correlated to clinicopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS) and carcinoma-specific survival (CSS). RESULTS: We have analyzed 334 patients with NMIBC at stage pT1 for mRNA analysis. Data from 296 patients (79% male, median age: 72 years) could be used. Spearman correlation revealed significant associations between mRNA expressions of PD1/PDL1 (ρ: 0.6024, p < 0.0001), CD3/PDL1 (ρ: 0.5728, p < 0.0001) and CD3/PD1 (ρ: 0.7005, p < 0.0001). Kaplan-Meier analysis revealed that high PDL1 mRNA expression (≥ 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021]. CONCLUSION: High mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy.
Authors: Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir Journal: Mol Diagn Ther Date: 2022-02-01 Impact factor: 4.074
Authors: Markus Eckstein; Ralph M Wirtz; Carolin Pfannstil; Sven Wach; Robert Stoehr; Johannes Breyer; Franziska Erlmeier; Cagatay Günes; Katja Nitschke; Wilko Weichert; Wolfgang Otto; Bastian Keck; Sebastian Eidt; Maximilian Burger; Helge Taubert; Bernd Wullich; Christian Bolenz; Arndt Hartmann; Philipp Erben Journal: Oncotarget Date: 2018-02-19
Authors: Markus Eckstein; Pamela Strissel; Reiner Strick; Veronika Weyerer; Ralph Wirtz; Carolin Pfannstiel; Adrian Wullweber; Fabienne Lange; Philipp Erben; Robert Stoehr; Simone Bertz; Carol Imanuel Geppert; Nicole Fuhrich; Helge Taubert; Sven Wach; Johannes Breyer; Wolfgang Otto; Maximilian Burger; Christian Bolenz; Bastian Keck; Bernd Wullich; Arndt Hartmann; Danijel Sikic Journal: J Immunother Cancer Date: 2020-05 Impact factor: 13.751
Authors: Jeffrey S Damrauer; Kyle R Roell; Markia A Smith; Melissa A Troester; Eugene J Pietzak; Xuezheng Sun; Erin L Kirk; Katherine A Hoadley; Halei C Benefield; Gopakumar Iyer; David B Solit; Matthew I Milowsky; William Y Kim; Matthew E Nielsen; Sara E Wobker; Guido Dalbagni; Hikmat A Al-Ahmadie; Andrew F Olshan; Bernard H Bochner; Helena Furberg Journal: Clin Cancer Res Date: 2021-06-11 Impact factor: 13.801